ClinicalTrials.gg
RecruitingNCT07017933GRADIENTUpdated Mar 19, 2026

Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes

An interventional study of Renal assist device in Renal Impairment After Cardiac Surgery, Renal Impairment and Acute Kidney Injury, sponsored by 3ive Labs. Recruiting at 7 sites in 2 countries. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Primary conditionAcute Kidney InjuryRegistry: Renal InsufficiencyReclassifiedWhy we changed it
Registry
Renal Insufficiency — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acute Kidney Injury
Why
  1. The study's listed conditions name Acute Kidney Injury, a narrower term within Renal Insufficiency.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by 3ive Labs · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
84th of 237
124 · median 67
Started
2025
with 21 others
No phase
106 of 370
25 open now
Primary completion
2026-12
later than 22 of 87 live
Registered
338th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 84th largest by planned enrollment of the 237 interventional ones that give a count, is one of 22 that started in 2025, is one of 106 with no phase, reaches primary completion later than 22 of the 87 other live ones, and was the 338th registered.

Acute Kidney Injury

1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively. This in turn is associated with an increased risk of prolonged intensive care unit (ICU) length of stay, other comorbidities including surgical complications and 30-day mortality. Renal impairment is generally identified based on an increase in serum creatinine concentration and/or a certain magnitude decrease in estimated glomerular filtration rate (eGFR).

The JuxtaFlow® Renal Assist Device (RAD) is designed to sustain or enhance glomerular filtration perioperatively for patients with renal insufficiency by applying a mild controlled negative pressure to the collecting system via the renal pelvis, thereby increasing effective filtration pressure and reducing tubular pressure. This mechanism is designed to support the kidneys' functions during times of renal stress that would be associated with intrarenal edema, volume overload, increased venous pressure, and inflammatory response. By supporting renal function, specifically during the acute stress of CPB, JuxtaFlow holds promise to protect nephron function, decrease renal hypoxia, and provide multifactorial kidney function support to maintain their ability to manage future stress.

03

Conditions studied

  • Renal Impairment After Cardiac Surgery
  • Renal Impairment
  • Acute Kidney Injury

Browse trials for

Keywords

  • renal assist device
  • RAD
  • renal impairment
  • acute kidney disease
  • JuxtaFlow
04

In context

Acute Kidney Injury Reclassified

1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

This study's planned enrollment of 124 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

3ive Labs is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Acute Kidney Injury, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for participation in this study, an individual must meet all the following criteria:

  1. A candidate for elective or urgent on-pump coronary artery bypass grafting (CABG) and/or valvular surgery
  2. Male or Female age 22 to 85 years
  3. Estimated (eGFR) 15 - 60 mL/min/1.73m2
  4. Signed and dated
  5. Female patients of must:

    1. have negative pregnancy test at the informed consent visit,
    2. be using previously initiated approved and effective from the informed consent visit through completion of the study *The only recommended contraception is condoms.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Any individual, or their legally authorized representative (LAR), who does not understand the requests and risks of participating in the clinical trial or is unable to give
  2. Pregnancy or lactation
  3. Prior cardiac surgery within the last 6 months
  4. Hemodynamic instability as determined by the Principal Investigator
  5. Active infections (e.g. , Tbc, and all types of Hepatitis)
  6. History of polycystic kidney disease
  7. Patients with only one active kidney or one poorly functioning kidney
  8. Evidence of current kidney obstruction (e.g., Kidney stones)
  9. Evidence of current hydronephrosis
  10. Active upper and/or lower urinary tract infections
  11. ; oncological Surgery within 5 years or ongoing antitumoral treatment
  12. Ongoing sepsis or endocarditis
  13. Patients who have an expected 30-day postoperative mortality greater than 10% as determined by the Principal Investigator
  14. Any secondary condition as determined by the investigator that would place the subject at an increased risk or preclude the subject's full compliance with the study procedures, including injuries to the urinary organs and/or external genitals; or severe BPH
  15. Unexplained/unexpected gross hematuria as determined by the Investigator
  16. Current or planned treatment with an drug (IND), device (IDE), or other investigational intervention within 3 months prior to or during participation in this clinical trial
  17. Patients who have a current unrepaired ureteral avulsion as determined by the investigator
  18. Patients otherwise for urological interventions, including ureter guidewire placement via bladder cystoscopy and ureteral catheterization, or otherwise contraindicated for any of the other study procedures
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    A standard bladder catheter (i.e. Foley) will be placed for bladder urine collection peri-operatively for up to 72 hours while in critical care. No JuxtaFlow catheters will be placed in control subjects.

  • Experimental
    Renal Assist Device

    Subjects randomized to the Treatment group will receive up to 72 hours of controlled negative pressure (-15mmHg) into the renal pelvis of each kidney. Treatment will be discontinued when the subject is transferred out of critical care after at least 24 hours of treatment. A standard bladder catheter (i.e. Foley) will also be placed for bladder urine collection peri-operatively for up to 72 hours.

    Device: Renal assist device

Interventions

  • DeviceRenal assist device

    The JuxtaFlow RAD includes two endoscopically placed ureteral catheters connected to a bedside pump system. The catheters are designed to deliver a mild, controlled negative pressure (-15 mmHg ± 2mmHg) into the renal pelvis of each kidney for up to 72 hours. This pressure is designed to diffuse through each of the million nephrons lowering intratubular pressure thereby improving the filtration gradient at the glomerulus while supporting overall kidney function.

    Also known as: RAD, JuxtaFlow

07

What researchers measure

Primary outcomes

  1. Mean Peak Percent Change in Serum Creatinine

    The mean peak percent change in serum creatinine from baseline values (prior to treatment) within the first 96 hours post-surgery for JuxtaFlow treated subjects as compared to controls.

    Time frame: 96 hours peri-operative

  2. Incidence of Treatment-Emergent Adverse Events

    The characterization and comparison of all types, frequency, and severity of adverse events (AEs) associated with JuxtaFlow treatment and controls.

    Time frame: From enrollment to post-operative day 30

Secondary outcomes

  1. AUC Serum Creatinine

    The area under the curve of serum creatinine changes from baseline values (prior to treatment) up to 96 hours post-surgery for JuxtaFlow treated subjects as compared to controls.

    Time frame: 96 hours peri-operative

  2. Creatinine Clearance

    The average creatinine clearance as a measure of acute glomerular filtration rate, assessed for a minimum of 24 and up to 48 hours in 8-hour intervals during postoperative ICU JuxtaFlow treatment as compared to controls.

    Time frame: 24 to 48 hours post-operatively

  3. AKI incidence

    The incidence of acute kidney injury (as determined by the KDIGO criteria) during post-surgical hospitalization and 14 days post-surgery with treatment as compared to controls.

    Time frame: From post-operative day 1 to 14

  4. Critical Care Length of Stay

    The post-surgical critical care length of stay (LOS) in the United States cohort for JuxtaFlow treated subjects as compared to controls.

    Time frame: through study study completion, an average of 1 year

Other outcomes

  1. AKI severity

    The severity and duration of acute kidney injury (as determined by the KDIGO criteria) during post-surgical hospitalization and 14 days post- surgery with treatment as compared to controls.

    Time frame: From post-operative day 1 to 14

  2. Urine Electrolytes

    The change in urine sodium and potassium excretion rates during the treatment period (up to 72 hours) as compared to controls. Urine output will be assessed in 8-hour intervals perioperatively.

    Time frame: Up to 72 hours peri-operatively

  3. eGFR

    The change in eGFR (measured by 2021 EPI Cr method) measured at baseline, perioperatively, and at 14- and 30-days post-surgery in JuxtaFlow treated subjects as compared to controls.

    Time frame: From enrollment to post-operative day 30

  4. Urine Output

    The change in urine output (i.e. volume, urine flow, total oliguria time, total anuria time, etc.) over the course of treatment (up to 72 hours) as compared to controls. Urine output will be assessed in 8-hour intervals perioperatively.

    Time frame: Up to 72 hours peri-operatively

  5. Hospital Length of Stay

    The post-surgical hospital length of stay (LOS) in the United States cohort for JuxtaFlow treated subjects as compared to controls.

    Time frame: through study study completion, an average of 1 year

  6. Anemia Incidence

    The incidence of anemia (as defined by a nadir hematocrit below 23% for women and 28% for men after initiating the investigational treatment) assessed immediately after starting treatment, immediately after surgery, and at every postoperative 8-hour period during treatment (up to 72-hours) after initiation of the treatment, and daily during the post-treatment period (until hospital discharge) as compared to controls.

    Time frame: through study study completion, an average of 1 year

  7. Electrolyte abnormalities

    The incidence of electrolyte abnormalities (as defined by any alteration in the metabolic panel according to the reference values after initiating the investigational treatment) assessed immediately after starting JuxtaFlow treatment, immediately after surgery, and at every postoperative 8-hour period during treatment (up to 72-hours) after initiation of the investigational treatment, and daily during the post-treatment period (until hospital discharge). Assessed by comprehensive metabolic panel (includes calcium, sodium, potassium and carbon dioxide) and excretion rates calculated from a Urinalysis panel (includes sodium and potassium).

    Time frame: through study study completion, an average of 1 year

  8. Azotemia

    The incidence of azotemia or elevated blood urea nitrogen (BUN).

    Time frame: through study study completion, an average of 1 year

  9. Dialysis Incidence

    The incidence of dialysis within 30 days post-surgery.

    Time frame: From post-operative day 1 to 30

  10. Hospital Readmission

    Readmission to in-patient hospitalization for any reason within the 30- day postoperative period.

    Time frame: From post-operative day 1 to 30

  11. Mortality

    All-cause mortality at 30 days post-surgery.

    Time frame: From post-operative day 1 to 30

08

Study locations

6 of 7 sites recruiting
09

References and documents

Publications

  • Rodriguez E, Petrovic M, Milewski K, et al. Feasibility Study of Renal Negative Pressure Treatment after Cardiac Surgery with Cardiopulmonary Bypass. Ann Thorac Surg Short Rep. 2026 Feb 25. doi: [DOI]. Epub ahead of print.
  • Rao VS, Maulion C, Asher JL, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Wilcox CS, Testani JM. Renal negative pressure treatment as a novel therapy for heart failure-induced renal dysfunction. Am J Physiol Regul Integr Comp Physiol. 2021 Oct 1;321(4):R588-R594. doi: 10.1152/ajpregu.00115.2021. Epub 2021 Aug 18. PubMed 34405731 ↗

Related links

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 269 interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
Jun 12, 2025
StartActual
Jul 16, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 14, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07017933
Lead sponsor
3ive Labs
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Jul 16, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 14, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Allison Fenderson, RN, MSHS, CCRP
Contact
gradient@3ivelabs.com
919-744-5703
Alencia Washington, PhD
Contact
gradient@3ivelabs.com
Evelio Rodriguez, MD
principal investigator · Ascension Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion